A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide

Diagnostic Microbiology and Infectious Disease

Volumn 28, Issue 4, 1997, Pages 157-163

  Pfaller, Michael A ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM;

ANAEROBIC BACTERIUM; BACTERICIDAL ACTIVITY; BURKHOLDERIA CEPACIA; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; EUROPE; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; NEISSERIA MENINGITIDIS; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; CEFTAZIDIME; DRUG RESISTANCE, MICROBIAL; EUROPE; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MULTICENTER STUDIES; NORTH AMERICA; THIENAMYCINS;

EID: 0030819621     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00065-5     Document Type: Review

References (32)

1. Bauernfeind A, Jungwirth R, Schweighart S (1989) in vitro activity of meropenem, imipenem, and penem HRE 664 and ceftazidime against clinical isolates from West Germany. J Antimicrob Chemother 24(suppl A):73-84.
2. Bush K (1989a) Minireviews: Characterization of β-lactamases. Antimicrob Agents Chemother 33:259-263.
3. Bush K (1989b) Classification of β-lactamases: Groups 1, 2a, 2b, and 2b′. Antimicrob Agents Chemother 33:264-270.
4. Bush K (1989c) Classification of β-lactamases: Groups 2c, 2d, 2e, 3, and 4. Antimicrob Agents Chemother 33:271-276.
5. Chanal C, Sirot D, Chanal M, Cluzel M, Sirot J, Cluzel R (1989) Comparative in vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum β-lactamases. J Antimicrob Chemother 24(suppl A):133-141.
6. Chanal C, Sirot D, Romaszko JP, Bret L, Sirot J (1996) Survey of extended β-lactamases among Enterobacteriaceae. J Antimicrob Chemother 38:127-132.
7. Edwards JR (1995) Meropenem: A microbiological overview. J Antimicrob Chemother 36(suppl A):1-17.
8. Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano I, Sanchez de San Lorenzo A (1991) Meropenem: In vitro activity and kinetics of activity against organisms of the Bacteroides fragilis group. J Antimicrob Chemother 27:599-606.
9. Hoban DJ, Jones RN, Yamane N, Frei R, Trilla A, Pignatari AC (1993) In vitro activity of three carbapenem antibiotics: Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated world-wide. Diagn Microbiol Infect Dis 17:299-305.
10. Jones RN, Aldridge KE, Allen SD, Barry AL, Fuchs PC, Gerlach EH (1989a) Multicenter in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother 33:562-565.
11. Jones RN, Barry AL, Thornsberry C (1989b) In vitro studies of meropenem. J Antimicrob Chemother 24(suppl A):9-29.
12. Jones RN (1992) The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens. Diagn Microbiol Infect Dis 15(suppl):3S-10S.
13. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, the Fluoroquinolone Resistance Surveillance Group (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn Microbiol Infect Dis 19:203-215.
14. Jorgensen JH, Maher LA, Howell AW (1991) Activity of a new carbapenem antibiotic, meropenem, against Haemophilus influenzae strains with β-lactamase and non-enzyme-mediated resistance to ampicillin. Antimicrob Agents Chemother 35:600-602.
15. Kayser FH, Morenzoni G, Strassle A, Hadorn K (1989) Activity of meropenem against Gram-positive bacteria. J Antimicrob Chemother 24(suppl A):101-112.
16. Kitzis MD, Acar JF, Gutmann L (1989) Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect and against staphylococci. J Antimicrob Chemother 24(suppl A):125-132.
17. Kitzis MD, Liassine N, Ferre B, Gutmann L, Acar JF, Goldstein F (1990) In vitro activity of 15 oral β-lactams against Klebsiella pneumoniae harboring new extended spectrum β-lactamases. Antimicrob Agents Chemother 34: 1783-1786.
18. Labia R, Morand A, Tiwari K, Sirol D, Chanal C (1989) Interactions of meropenem with β-lactamases including new enzymes with extended-spectrum activity against third-generation cephalosporins. J Antimicrob Chemother 24(suppl A):219-223.
19. Medeiros AA (1997) Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 24(suppl 1):S19-S45.
20. Murray PR, Niles AC (1990) In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates. Diagn Microbiol Infect Dis 13: 57-61.
21. National Committee for Clinical Laboratory Standards (NCCLS) (1993) Approved Standard M11-A3: Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 3rd ed. Villanova, PA: NCCLS.
22. National Committee for Clinical Laboratory Standards (NCCLS) (1997) Approved Standard M7-A4: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 4th ed. Wayne, PA: NCCLS.
23. Nord CE, Lindmark A, Persson I (1989) Susceptibility of anaerobic bacteria to meropenem. J Antimicrob Chemother 24(suppl A):113-117.
24. Philippon A, Arlet G, Lagrange PH (1994) Origin and impact of plasmid-mediated extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis 13:17-29.
25. Pitkin DH, Sheikh W, Nadler HL (1997) Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers. Clin Infect Dis 24(suppl 2):S238-S248.
26. Sanders CC, Sanders WE, Thompson KS, Iaconis JP (1989) Meropenem: Activity against resistant Gram-negative bacteria and interactions with β-lactamases. J Antimicrob Chemother 24(suppl A):187-196.
27. Schito GC, Sanna A, Chezzi C, Ravizzola G, Leone F, Molinari G (1989) In vitro activity of meropenem against clinical isolates in a multicentre study in Italy. J Antimicrob Chemother 24(suppl A):57-72.
28. Shah P, Stille W (1992) Activity of meropenem and other antimicrobials against Enterobacteriaceae and Pseudomonas aeruginosa isolated in Frankfurt during 1989 and 1991. Spanish J Chemother 5(suppl 4):61-64.
29. Swartz MN (1994) Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci USA 91:2420-2427.
30. Wiedemann B, Zuhlsdorf M (1989) Antibacterial properties of meropenem towards clinical isolates, β-lactamase producers and laboratory mutants. J Antimicrob Chemother 24(suppl A):197-205.
31. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM (1995) Meropenem: A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50: 73-101.
32. Yang Y, Livermore DM (1989) Interactions of meropenem with class I chromosomal β-lactamases. J Antimicrob Chemother 24(suppl A):207-217.